Our data suggests that use of G-CSF, GM-CSF or other myeloid chemoattractant-based therapies in older adults would enhance recruitment of a population that is fundamentally immature and predisposed towards TNF and IL6 production that provides no functional benefit to the host for clearance and may even exacerbate infection. This evidence concerns the gene TNF and infection.